Researchers studied the effect of lower extremity involvement on exercise, function, and quality of life in the peripheral predominant forms of juvenile idiopathic arthritis.
In a nested cohort study, researchers highlighted the value of patient-reported outcomes in the management of patients with polyarticular juvenile idiopathic arthritis.
Researchers defined and validated serum biomarker profiles to differentiate between primary hemophagocytic lymphohistiocytosis (HLH), secondary HLH, and macrophage activation syndrome associated with systemic juvenile idiopathic arthritis.
Researchers assessed the prevalence and characteristics of musculoskeletal manifestations of childhood cancers and identified the factors that differentiated them from juvenile idiopathic arthritis.
Researchers evaluated the relationship of adalimumab trough concentrations and treatment response in patients with juvenile idiopathic arthritis.
Professor A.V. Ramanan, a consultant pediatric rheumatologist and the co-author of a recent review paper, provides updates on the status of treatments for juvenile idiopathic arthritis.
Researchers assessed whether methotrexate-induced nausea in JIA was associated with single-nucleotide polymorphisms in genes encoding MTX transporter proteins.
Researchers evaluated the outcomes in patients with persistent oligoarticular JIA vs extended oligoarticular JIA and rheumatoid factor-negative polyarthritis who received methotrexate.
Adolescent patients with chronic rheumatic disease can be at risk for mental health issues that could cause a lower quality of life and impact their illness. What are some of these concerns?
Researchers assessed quality of life, mental health, physical disability, and vision-related functioning in children with juvenile idiopathic arthritis and noninfectious uveitis.
